Birth certificate

Fisher House Foundation's Hotels for Heroes help Navy family care for premature son

Retrieved on: 
Thursday, January 19, 2023
Honey, Transport, Fisher House, Birth certificate, Fisher House Foundation, Emotion, Child, VA, Navy, Family, Hotel, NICU, Eating, Water, Spouse, Snack, Marriage, Multimedia, Medicine, Tourism, Hospital

This premature birth would make a long stay in the neonatal intensive care unit at the hospital necessary.

Key Points: 
  • This premature birth would make a long stay in the neonatal intensive care unit at the hospital necessary.
  • After they learned they would be staying a little longer, they took the advice of a case worker to use Fisher House Foundation's Hotel for Heroes program.
  • "I like to think I'm pretty proud, and it sounded like charity, so I refused it in the beginning," Nathan said.
  • All the emotions of having a premature baby, recovering from an emergency C-section, and being away from family hit Erica all at once as they switched hotels.

CareSource Foundation Opens New $400,000 Funding Competition for Florida Organizations Supporting Medically Complex Children

Retrieved on: 
Tuesday, January 10, 2023
Birth certificate, Caregiver, Child, Medicaid, Organization, CareSource, Health, Grant, Health equity, Poverty, Women & Children First (bookstore), Pharmaceutical industry, Medicine

Jacksonville, FL, Jan. 10, 2023 (GLOBE NEWSWIRE) -- The CareSource Foundation announced today that nonprofit organizations in Florida will soon be eligible for funding through the CareSource Foundation Grant Challenge .

Key Points: 
  • Jacksonville, FL, Jan. 10, 2023 (GLOBE NEWSWIRE) -- The CareSource Foundation announced today that nonprofit organizations in Florida will soon be eligible for funding through the CareSource Foundation Grant Challenge .
  • The CareSource Foundation Grant Challenge will award a total of $400,000 to Florida community-based organizations and nonprofits focused on demonstrating effective, practical solutions to address the needs of children and youth in medically complex care.
  • Florida is the fourth state where the CareSource Foundation Grant Challenge will take place.
  • Organizations interested in applying to the CareSource Foundation Grant Challenge should consult website for entry and nomination deadlines.

iTeos Provides Business Updates and Clinical Development Plans for 2023

Retrieved on: 
Monday, January 9, 2023
NSCLC, Large-cell lung carcinoma, Therapy, Immunotherapy, Multiple myeloma, Birth certificate, Tumor microenvironment, Partnership, Patient, Adenosine, GSK, Medical imaging, Pharmaceutical industry, Fine chemical, Vaccine

WATERTOWN, Mass. and GOSSELIES, Belgium, Jan. 09, 2023 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today outlined business updates that are anticipated to advance its position in 2023, building a path to registration for its promising immunotherapy portfolio.

Key Points: 
  • and GOSSELIES, Belgium, Jan. 09, 2023 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today outlined business updates that are anticipated to advance its position in 2023, building a path to registration for its promising immunotherapy portfolio.
  • In 2023, we will continue to progress our broad clinical plan against validated targets and benefit from informative readouts across the field.
  • “Leveraging our scientific expertise, drug development capabilities, financial resources, and our strong partnership with GSK, we are in an enviable position as we kick off 2023.
  • New clinical development program with the potential to fully reverse adenosine immune suppression, in combination with inupadenant, but also other standards of care.

South Carolina Donors Honored During 134th Donate Life Rose Parade

Retrieved on: 
Thursday, January 5, 2023
Lifting, Friends, Health, Birth certificate, SHSC, Hope, SC, The Bridge: The Life and Rise of Barack Obama, Ellenberg, Motor vehicle, Eye, Parent, Rose Parade, Donate Life America, Entertainment, Toy, Pharmaceutical industry

CHARLESTON, S.C., Jan. 5, 2023 /PRNewswire/ -- We Are Sharing Hope SC (SHSC), Bridge to Life, Donate Life South Carolina, Global Transplant Solutions, Inc., and the South Carolina Department of Motor Vehicles participated in the 134th Rose Parade in Pasadena, California.

Key Points: 
  • CHARLESTON, S.C., Jan. 5, 2023 /PRNewswire/ -- We Are Sharing Hope SC (SHSC), Bridge to Life, Donate Life South Carolina, Global Transplant Solutions, Inc., and the South Carolina Department of Motor Vehicles participated in the 134th Rose Parade in Pasadena, California.
  • The South Carolina based groups honored the Ellenberg family and others as the Donate Life Rose Parade® float travelled down Colorado Blvd, with the mission of inspiring others to be a registered donor.
  • "The message of lifting each other up is essential in this year's participation in the Donate Life Rose Parade float," said Tracy Moore, CEO of Donate Life South Carolina.
  • Bridge to Life, a global provider of medical devices with operations in Columbia, South Carolina, has worked closely with the Rose Parade and the Donate Life float, sending families to Pasadena impacted by organ donation since 2010.

ObsEva Evidences Compliance with Nasdaq’s Stockholder’s Equity Rule and Announces Moratorium Dismissal Request Filing

Retrieved on: 
Wednesday, December 14, 2022
Woman, Annual report, Coronavirus, Inflammation, Birth certificate, Security (finance), Letter, Sale, SIX Swiss Exchange, Transaction, Risk, Pregnancy, Form 6-K, Fertilisation, Organon

Nasdaq Listing Rule 5450(b)(1)(A) requires listed companies listed on the Nasdaq Global Select Market to maintain stockholders’ equity of at least $10.0 million.

Key Points: 
  • Nasdaq Listing Rule 5450(b)(1)(A) requires listed companies listed on the Nasdaq Global Select Market to maintain stockholders’ equity of at least $10.0 million.
  • In July 2021, ObsEva granted a license to Organon for the global development, manufacturing, and commercial rights to Ebopiprant.
  • The Company therefore believes that as of the date hereof the Company has regained compliance with Nasdaq Listing Rule 5450(b)(1)(A).
  • There can be no assurance that the Company will be able to maintain compliance with the minimum stockholders’ equity requirement.

Chiesi USA Announces Publication of Health Economics Analysis of Selective Early Rescue Surfactant Administration vs. Standard Surfactant Administration for Premature Infants with Respiratory Distress Syndrome

Retrieved on: 
Tuesday, November 29, 2022
Oxygen, Bradycardia, Patient, Respiratory disease, Environment, Fraction of inspired oxygen, Benefit corporation, Degenerative disease, Premature, Late preterm infant, Intracranial hemorrhage, Pneumonia, Knowledge, Community, Therapy, Intubation, Health, Mortality, Lung compliance, Birth certificate, Pulmonary interstitial emphysema, Bronchopulmonary dysplasia, Pneumothorax, RDS, Respiratory distress syndrome, Neonatology, Pulmonary hemorrhage, B Corporation (certification), Journal, Pharmacology, Cystic fibrosis, Hypotension, Research, Birth weight, Resuscitation, Infant respiratory distress syndrome, Health insurance, Pharmaceutical industry, Environmental remediation, Fine chemical, Chiesi Farmaceutici

CARY, N.C., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Chiesi USA (key-ay-zee), the U.S. affiliate of Chiesi Farmaceutici, an international research-focused healthcare group (Chiesi Group), today announced the publication of an article describing a health economic model comparing selective early rescue surfactant administration versus standard surfactant administration for infants with respiratory distress syndrome (RDS).

Key Points: 
  • CARY, N.C., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Chiesi USA (key-ay-zee), the U.S. affiliate of Chiesi Farmaceutici, an international research-focused healthcare group (Chiesi Group), today announced the publication of an article describing a health economic model comparing selective early rescue surfactant administration versus standard surfactant administration for infants with respiratory distress syndrome (RDS).
  • Early selective surfactant administration, such as use of the INtubation SURfactant Extubation (INSURE)* technique was compared to a base case of standard surfactant administration via endotracheal intubation and mechanical ventilation.
  • CUROSURF Intratracheal Suspension is a surfactant indicated for the rescue treatment, including the reduction of mortality and pneumothoraces, of respiratory distress syndrome (RDS) in premature infants.
  • The authors conclusions suggest that selective early rescue surfactant administration strategies are associated with a lower healthcare burden in premature infants with RDS.

ObsEva Announces Sale of Ebopiprant License Agreement to XOMA for up to $113 Million

Retrieved on: 
Tuesday, November 22, 2022
Report, Pharmacokinetics, Risk, Merck Group, Female, SIX Swiss Exchange, Consent, Birth certificate, Inflammation, Drug development, Security (finance), Center for Drug Evaluation and Research, Letter, Sale, Fertilisation, Coronavirus, Woman, Cleveland Cultural Gardens, Pregnancy, Amendment, Safety, Form 6-K, JGB, Life insurance, Pharmaceutical industry, Organon

The sale of the Ebopiprant license agreement both strengthens our immediate financial position, while providing the potential for future upside for shareholders,said Brian OCallaghan, CEO of ObsEva.

Key Points: 
  • The sale of the Ebopiprant license agreement both strengthens our immediate financial position, while providing the potential for future upside for shareholders,said Brian OCallaghan, CEO of ObsEva.
  • ObsEva retains worldwide, exclusive, commercial rights for nolasiban, except for the Peoples Republic of China.
  • In addition to the $15 million received in upfront proceeds, ObsEva is eligible to receive up to $98 million upon the achievement of certain development and regulatory milestones and sales milestones under the Companys license agreement with Organon for Ebopiprant that was sold to XOMA in the transaction.
  • In July 2021, ObsEva granted a license to Organon for the global development, manufacturing, and commercial rights to Ebopiprant.

Daré Bioscience Announces Grant to Develop Novel Hydrogel Formulation for Delivery of Live Biotherapeutics to Support Vaginal Health

Retrieved on: 
Tuesday, November 15, 2022
Cream, COVID-19, Doctor of Philosophy, SAN, Recurrence, Fertility, Health minister, Infection, Food, Menopause, Risk, Female, Safety, Social media, Bill, Patient, Regulation of tobacco by the U.S. Food and Drug Administration, Birth certificate, Bacterial vaginosis, Birth, Sale, 8-K, Health, Therapy, Progesterone, Intellectual property, Form, Failure, Bill & Melinda Gates Foundation, Woman, FDA, Pharmaceutical industry, Birth control, Bayer, Organon

SAN DIEGO, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced it has received a grant from the Bill & Melinda Gates Foundation (the foundation) of $584,986 to support activities related to development of a vaginal thermosetting gel formulation for the delivery of live biotherapeutics that can be reconstituted at the point of care. If successful, the formulation could be carried forward for further development as a delivery vehicle with potential to enhance the availability of novel therapeutics for vaginal health in the United States and worldwide, including in countries with varying climatic conditions and/or where extended storage may be required.

Key Points: 
  • However, there remains a clear and unmet need for products that can be administered following effective treatment of the primary vaginal infection to then rebalance the vaginal microbiota and promote continued improved vaginal health.
  • This grant will enable us to investigate the use of a novel hydrogel technology to deliver live biotherapeutics to address this challenge that affects women everywhere.
  • We are grateful for the foundations support in advancing this technology with the goal of making such therapies available to women worldwide.
  • Dar cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements.

THIS WORLD PREMATURITY DAY, PAMPERS CONTINUES TO TOUCH THE LIVES OF PREEMIE BABIES BOTH NEAR AND FAR BY HELPING CHARITIES BLISS AND UNICEF

Retrieved on: 
Thursday, November 17, 2022
Quality of life, Family, Hospital, COVID, Prenatal care, Birth certificate, Survival, UNICEF, Pharmacy, Woman, Mother, Pampers, Survival rate, Parent, Birmingham Women's Hospital, Oxytocin, Life, Sibling, Premature, World Prematurity Day, ASDA, Medicine, Toy, Asda, Bliss

In the UK, preemie care has had its advancements however parents still face challenges when it comes to bonding with their babies through touch.

Key Points: 
  • In the UK, preemie care has had its advancements however parents still face challenges when it comes to bonding with their babies through touch.
  • This World Prematurity Day, Pampers is taking their commitment one-step further, touching the lives of Preemie babies both near and far.
  • Our partnerships with both Bliss and UNICEF will help support moments of touch which is vital in the early stages of care for preemie babies.
  • You can show your support and help touch the lives of preemie babies near and far too.

Pampers® Canada partners with the Canadian Premature Babies Foundation and Préma-Québec to support NICU families

Retrieved on: 
Thursday, November 17, 2022
Shoulder, NICU, Quality of life, Ontogeny, Febreze, Procter & Gamble, Uncertainty, World Prematurity Day, Walmart Canada, Neonatology, Gillette, News, Vicks, Organization, Partnership, Nursing, Mental health, Education, Research, NYSE, Pantene, Head & Shoulders, Parent, Birth certificate, Walmart, PG, P&G, Premature, Grocery store, Medicine, Toy, Information technology, Skin, Pampers, Crest, Whispering, Tide

Now, in recognition of World Prematurity Day and November's Prematurity Awareness Month, Pampers Canada is partnering with the Canadian Premature Babies Foundation (CPBF) and Prma-Qubec to support families with premature babies.

Key Points: 
  • Now, in recognition of World Prematurity Day and November's Prematurity Awareness Month, Pampers Canada is partnering with the Canadian Premature Babies Foundation (CPBF) and Prma-Qubec to support families with premature babies.
  • This funding will go towards support programs for families of premature babies, including mental health and wellness resources.
  • Through these generous donations from Pampers Canada, we will be able to continue this support for Canadian families," said Fabiana Bacchini, Executive Director, Canadian Premature Babies Foundation.
  • As a parent-led charity, the Canadian Premature Babies Foundation (CPBF) supports and educates families of babies born prematurely.